Top Markets
#1 NKN NKN +160.00%
#2 Bluwhale Bluwhale +34.89%
#3 Codatta Codatta +30.46%
#4 SAFEcoin SAFEcoin +28.54%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.16%
#7 Particle Network Particle Network +18.79%
#8 Yooldo Games Yooldo Games +15.38%
#9 Arcblock Arcblock +14.06%
#10 Ski Mask Dog Ski Mask Dog +13.94%
Coin of the day
NKN NKN
설정
언어
한국어
통화
USD
테마
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
주식 순위 #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
주가
$0.15
시가총액
$4.96M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
CA
거래 Intellipharmaceutics International Inc. (IPCIF)

카테고리

Healthcare
Intellipharmaceutics International Inc. (IPCIF)의 매출
Aug 2023 기준 매출 TTM: $904.95K
Intellipharmaceutics International Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $904.95K입니다. 2021년에 회사는 $65.73K의 수익을 올렸으며 이는 2020년의 $1.40M 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Intellipharmaceutics International Inc.의 수익 기록 (1999 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $904.95K 1,276.80%
2022 $65.73K 0.00%
2021 $65.73K -95.31%
2020 $1.40M 0.00%
2019 $1.40M -18.17%
2018 $1.71M -68.88%
2017 $5.50M 144.97%
2016 $2.25M -45.11%
2015 $4.09M -53.32%
2014 $8.77M 474.13%
2013 $1.53M 1,326.33%
2012 $107.09K -78.66%
2011 $501.81K -65.61%
2010 $1.46M 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 $1.00K 0.02%
2000 $999.82 -99.00%
1999 $100.06K 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 5,352,315.73%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 1,330,189.32%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 1,584,845.40%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 1,003,525.57%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 606,708.00%
NL